From etiology to precision oncology: a systematic review of the causes and evolving treatments of prostate cancer.
- 1Kabale University School of Medicine, Kabale, Uganda.
- 2Victoria University, Kampala, Uganda.
Abstract
Background
Prostate cancer remains one of the most frequently diagnosed malignancies and a leading cause of cancer-related mortality among men globally. Its development is driven by a complex interaction of genetic susceptibility, molecular alterations, hormonal signaling, environmental exposures, and lifestyle-related factors. This systematic review synthesizes current evidence on the etiological mechanisms and evolving therapeutic landscape of prostate cancer.Methods
A systematic review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines. Literature published between January 2010 and December 2025 was searched in PubMed, Scopus, and Web of Science databases. Eligible studies included original research, clinical studies, translational studies, and experimental investigations evaluating prostate cancer etiology, molecular mechanisms, risk factors, biomarkers, or therapeutic interventions.Results
The review included 29 studies encompassing epidemiological cohorts, clinical studies, genomic analyses, tissue-based investigations, and preclinical experimental studies. Evidence demonstrated that prostate cancer etiology involves multiple interconnected pathways, including androgen receptor signaling, DNA repair alterations, genomic instability, chromatin remodeling, metabolic reprogramming, and inflammatory mechanisms. Genetic variants, including single nucleotide polymorphisms and polygenic risk scores, were associated with disease susceptibility, aggressiveness, treatment response, and toxicity outcomes. Therapeutic advances included optimization of androgen deprivation therapy, novel androgen receptor pathway inhibitors, chemotherapy, radiotherapy personalization, bone-targeted therapies, PSMA-directed radioligand therapy, and emerging immunotherapeutic approaches. Biomarker-driven strategies, including genomic classifiers and molecular signatures, showed potential for improving risk stratification and individualized treatment selection.Conclusion
Prostate cancer is a biologically heterogeneous disease requiring integrated approaches that combine molecular understanding with clinical decision-making. Recent advances in precision oncology have expanded therapeutic options beyond conventional treatment paradigms, enabling more personalized management strategies. However, further research is required to improve representation of diverse populations, validate biomarkers across different ethnic groups, and optimize the clinical implementation of emerging targeted and immune-based therapies.Systematic review registration
https://www.crd.york.ac.uk/PROSPERO/, identifier CRD420261435105.
Related
- Evolving role of proton therapy in contemporary oncology
- Five years of Discover Oncology: reflecting on a rapidly evolving field
- Precision surgical oncology for hepatocellular carcinoma
- Unravelling the biological divergence of CD30+ lymphoproliferative disorders with skin involvement: from clinical risk to precision oncology
- Evolution of Precision Oncology, Personalized Medicine, and Molecular Tumor Boards
BibTeX
@article{kisakye2026from,
title = {{From etiology to precision oncology: a systematic review of the causes and evolving treatments of prostate cancer.}},
author = {Nakitto Irene Kisakye and Geoffrey Ayebazibwe and Paula Mary Amito and Patricia D Ajambo and Michael Tirwomwe and Annet Tiko and Tusingwire Pliers and Asaph Owamukamaeli and Timothy Nduhukire and Ngabirano Chrispuss and Immaculate Mandera and Racheal Owomugisha and Swase Dominic Terkimbi},
journal = {Frontiers in oncology},
year = {2026},
month = oct,
doi = {10.3389/fonc.2026.1941788},
url = {https://europepmc.org/article/MED/42908603},
note = {CC BY},
}
RIS
TY - JOUR
TI - From etiology to precision oncology: a systematic review of the causes and evolving treatments of prostate cancer.
AU - Nakitto Irene Kisakye
AU - Geoffrey Ayebazibwe
AU - Paula Mary Amito
AU - Patricia D Ajambo
AU - Michael Tirwomwe
AU - Annet Tiko
AU - Tusingwire Pliers
AU - Asaph Owamukamaeli
AU - Timothy Nduhukire
AU - Ngabirano Chrispuss
AU - Immaculate Mandera
AU - Racheal Owomugisha
AU - Swase Dominic Terkimbi
PY - 2026
DA - 2026/10/07
JO - Frontiers in oncology
DO - 10.3389/fonc.2026.1941788
UR - https://europepmc.org/article/MED/42908603
AB - Background Prostate cancer remains one of the most frequently diagnosed malignancies and a leading cause of cancer-related mortality among men globally. Its development is driven by a complex interaction of genetic susceptibility, molecular alterations, hormonal signaling, environmental exposures, and lifestyle-related factors. This systematic review synthesizes current evidence on the etiological mechanisms and evolving therapeutic landscape of prostate cancer.Methods A systematic review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines. Literature published between January 2010 and December 2025 was searched in PubMed, Scopus, and Web of Science databases. Eligible studies included original research, clinical studies, translational studies, and experimental investigations evaluating prostate cancer etiology, molecular mechanisms, risk factors, biomarkers, or therapeutic interventions.Results The review included 29 studies encompassing epidemiological cohorts, clinical studies, genomic analyses, tissue-based investigations, and preclinical experimental studies. Evidence demonstrated that prostate cancer etiology involves multiple interconnected pathways, including androgen receptor signaling, DNA repair alterations, genomic instability, chromatin remodeling, metabolic reprogramming, and inflammatory mechanisms. Genetic variants, including single nucleotide polymorphisms and polygenic risk scores, were associated with disease susceptibility, aggressiveness, treatment response, and toxicity outcomes. Therapeutic advances included optimization of androgen deprivation therapy, novel androgen receptor pathway inhibitors, chemotherapy, radiotherapy personalization, bone-targeted therapies, PSMA-directed radioligand therapy, and emerging immunotherapeutic approaches. Biomarker-driven strategies, including genomic classifiers and molecular signatures, showed potential for improving risk stratification and individualized treatment selection.Conclusion Prostate cancer is a biologically heterogeneous disease requiring integrated approaches that combine molecular understanding with clinical decision-making. Recent advances in precision oncology have expanded therapeutic options beyond conventional treatment paradigms, enabling more personalized management strategies. However, further research is required to improve representation of diverse populations, validate biomarkers across different ethnic groups, and optimize the clinical implementation of emerging targeted and immune-based therapies.Systematic review registration https://www.crd.york.ac.uk/PROSPERO/, identifier CRD420261435105.
SN - 2234-943X
ER -